PR
202395
PR Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy
202376
PR Heartseed Announces Positive 26-week Data for the First Patient in the Phase 1/2 Clinical Trial (LAPiS Study) Dosed With HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure
2023525
PR Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure
2023314
PR Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences.
2023210
PR Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 - a cell therapy designed to restore heart function in people with advanced heart failure
2022914
PR Heartseed recognized as the "Most Promising Pipelines (iPSC Therapy) Award" at the APAC Cell and Gene Therapy Excellent Awards 2022.
2021810
PR Heartseed named "Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award" at Academic Startups 2021